Sweet’s syndrome in a granulocytopenic patient with acute myeloid leukemia on FLT3 inhibitor

INTRODUCTION: Gilteritinib is a FLT3 kinase inhibitor approved for FLT3-mutated acute myeloid leukemia (AML). We present a case of febrile neutropenia and neutrophilic dermatosis consistent with Sweet’s syndrome (SS). CASE HISTORY: A 55-year-old woman presented with fever and skin lesions after 4 we...

Descripción completa

Detalles Bibliográficos
Autores principales: Paudel, Anish, Dhital, Rashmi, Areoye, Gabriel, Basnet, Sijan, Tachamo, Niranjan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426991/
https://www.ncbi.nlm.nih.gov/pubmed/32850078
http://dx.doi.org/10.1080/20009666.2020.1766818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426991/
https://www.ncbi.nlm.nih.gov/pubmed/32850078
http://dx.doi.org/10.1080/20009666.2020.1766818

Ejemplares similares